The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma

References

• Adair JE, Johnston SK, Mrugala MM, et al. (2014). Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest 124:4082–92.
   PubMed Web of Science ®Google Scholar
• Basuki JS, Duong HT, Macmillan A, et al. (2013). Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release. ACS Nano 7:10175–89.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang M, Gan H, et al. (2018). A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949.
   PubMed Web of Science ®Google Scholar
• Danhier F, Messaoudi K, Lemaire L, et al. (2015). Combined anti-galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. Int J Pharm 481:154–61.
   PubMed Web of Science ®Google Scholar
• Du K, Xia Q, Heng H, Feng F. (2020). Temozolomide-doxorubicin conjugate as a double intercalating agent and delivery by apoferritin for glioblastoma chemotherapy. ACS Appl Mater Interfaces 12:34599–609.
   PubMed Web of Science ®Google Scholar
• Du Rietz H, Hedlund H, Wilhelmson S, et al. (2020). Imaging small molecule-induced endosomal escape of siRNA. Nat Commun 11:1809.
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Dietrich D, Fricker G, Lamprecht A. (2021). Blood-brain barrier models: rationale for selection. Adv Drug Deliv Rev 176:113859.
   PubMed Web of Science ®Google Scholar
• Hua D, Tang L, Wang W, et al. (2021). Improved antiglioblastoma activity and BBB permeability by conjugation of paclitaxel to a cell-penetrative MMP-2-cleavable peptide. Adv Sci (Weinh) 8:2001960.
   PubMedGoogle Scholar
• Hua L, Wang Z, Zhao L, et al. (2018). Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. Theranostics 8:5088–105.
   PubMed Web of Science ®Google Scholar
• Islam Y, Leach AG, Smith J, et al. (2021). Physiological and pathological factors affecting drug delivery to the brain by nanoparticles. Adv Sci (Weinh) 8:e2002085.
   PubMedGoogle Scholar
• Jiang T, Qiao Y, Ruan W, et al. (2021). Cation-free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy. Adv Mater 33:e2104779.
   PubMed Web of Science ®Google Scholar
• Johnson KC, Anderson KJ, Courtois ET, et al. (2021). Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet 53:1456–68.
   PubMed Web of Science ®Google Scholar
• Joshi N, Yan J, Levy S, et al. (2018). Towards an arthritis flare-responsive drug delivery system. Nat Commun 9:1275.
   PubMed Web of Science ®Google Scholar
• Joshi SK, Qian K, Bisson WH, et al. (2020). Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. Blood 135:2159–70.
   PubMed Web of Science ®Google Scholar
• Kang S, Duan W, Zhang S, et al. (2020). Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics 10:4308–22.
   PubMed Web of Science ®Google Scholar
• Karlsson J, Luly KM, Tzeng SY, Green JJ. (2021). Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. Adv Drug Deliv Rev 179:113999.
   PubMed Web of Science ®Google Scholar
• Kleber S, Sancho-Martinez I, Wiestler B, et al. (2008). Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235–48.
   PubMed Web of Science ®Google Scholar
• Liu J, Chang J, Jiang Y, et al. (2019). Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv Mater 31:e1902575.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng M, Jiao M, et al. (2021). Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy. Biomaterials 276:121036.
   PubMed Web of Science ®Google Scholar
• Meng X, Zhao Y, Han B, et al. (2020). Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways. Nat Commun 11:594.
   PubMed Web of Science ®Google Scholar
• Nicholson JG, Fine HA. (2021). Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov 11:575–90.
   PubMed Web of Science ®Google Scholar
• Otvos B, Alban TJ, Grabowski MM, et al. (2021). Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome. Clin Cancer Res 27:2038–49.
   PubMed Web of Science ®Google Scholar
• Qiao C, Yang J, Shen Q, et al. (2018). Traceable nanoparticles with dual targeting and ROS response for RNAi-based immunochemotherapy of intracranial glioblastoma treatment. Adv Mater 30:e1705054.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. (2019). The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18:421–46.
   PubMed Web of Science ®Google Scholar
• Sita TL, Kouri FM, Hurley LA, et al. (2017). Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proc Natl Acad Sci U S A 114:4129–34.
   PubMed Web of Science ®Google Scholar
• Tan AC, Ashley DM, Lopez GY, et al. (2020). Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70:299–312.
   PubMed Web of Science ®Google Scholar
• Tan J, Duan X, Zhang F, et al. (2020). Theranostic nanomedicine for synergistic chemodynamic therapy and chemotherapy of orthotopic glioma. Adv Sci (Weinh) 7:2003036.
   PubMedGoogle Scholar
• Tian M, Xing R, Guan J, et al. (2021). A nanoantidote alleviates glioblastoma chemotoxicity without efficacy compromise. Nano Lett 21:5158–66.
   PubMed Web of Science ®Google Scholar
• Wang K, Kievit FM, Chiarelli PA, et al. (2021). siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model. Adv Funct Mater 31(6):2007166.
   Web of Science ®Google Scholar
• Wang M, Lv CY, Li SA, et al. (2021). Near infrared light fluorescence imaging-guided biomimetic nanoparticles of extracellular vesicles deliver indocyanine green and paclitaxel for hyperthermia combined with chemotherapy against glioma. J Nanobiotechnology 19:210.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang Y, Wei D, et al. (2021). Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat Biomed Eng 5:1048–58.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang H, Xu S, et al. (2021). The adaptive transition of glioblastoma stem cells and its implications on treatments. Signal Transduct Target Ther 6:124.
   PubMed Web of Science ®Google Scholar
• Ward LD, Tu HC, Quenneville CB, Geisinger-Regeneron DiscovEHR Collaboration, et al. (2021). GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms. Nat Commun 12:4571.
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang G, Chen Y, et al. (2021). Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma. Bioact Mater 6:1330–40.
   PubMed Web of Science ®Google Scholar
• Xu H, Han Y, Zhao G, et al. (2020). Hypoxia-responsive lipid-polymer nanoparticle-combined imaging-guided surgery and multitherapy strategies for glioma. ACS Appl Mater Interfaces 12:52319–28.
   PubMed Web of Science ®Google Scholar
• Xu J, Liu Y, Liu S, et al. (2022). Metformin bicarbonate-mediated efficient RNAi for precise targeting of TP53 deficiency in colon and rectal cancers. Nano Today 43:101406.
   PubMed Web of Science ®Google Scholar
• Yang K, Wu Z, Zhang H, et al. (2022). Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21:39.
   PubMed Web of Science ®Google Scholar
• Yi GZ, Huang G, Guo M, et al. (2019). Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain 142:2352–66.
   PubMed Web of Science ®Google Scholar
• Zhang XN, Yang KD, Chen C, et al. (2021). Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Res 31:1072–87.
   PubMed Web of Science ®Google Scholar
• Zoulikha M, Xiao Q, Boafo GF, et al. (2022). Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome. Acta Pharm Sin B 12:600–20.
   PubMed Web of Science ®Google Scholar